Health Canada has cleared IntelGenx’s (OTCQX:IGXT; TSXV:IGX) clinical trial application for its Montelukast VersaFilm intended for the treatment of mild-to- moderate Alzheimer's disease (AD).Read More
Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.Read More
H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.Read More
An article on the Alzaforum website highlights IntelGenx (OTCQX:IGXT; TSXV:IGX) and its montelukast oral film candidate for the treatment of brain degenerative diseases, such as early-stage dementia.Read More
3D Signatures (TSX-V:DXD) has appointed Nigel Terrett to 3DS's business advisory board to provide the company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform.Read More
Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec 2.Read More
Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday.
AC Immune is focused on developing novel medicines for neurodegenerative disorders. Its lead asset, crenezumab, which is partnered with Roche/Genentech, is a monoclonal antibody that binds multiple sub-types of beta-amyloid.Read More
Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto.Read More
Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.
Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.Read More
ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.Read More
The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading BioPharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) to find therapies for Alzheimer’s disease.
The new center will be located at MGH. Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Merck and Sunovion Pharmaceuticals, have committed $1.25-million in Alzheimer’s-related research funding.Read More
ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the development of Alzheimer’s disease (AD).
“With multiple product candidates in our Ab program progressing to final validation and selection for drug development, we are focusing our science team and discovery processes on the other half of the root cause – tau prions.” SCO, Dr. Neil Cashman, explained in a statement.Read More
Stifel launched coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and 12-month target price of $23. The stock closed at $11.20 on Friday.
“Our bullish thesis centers on two key pipeline assets: AVP-786 in Phase 3 trials for Alzheimer’s agitation and CTP-543 in Phase 1 studies for alopecia areata,” writes analyst Adam Walsh.Read More